Serving as CEO of LifeBrite Laboratories, Christian Fletcher is an Atlanta entrepreneur who meets the needs of physicians and health care providers across the nation for reliable, accurate testing services. One aspect of what Christian Fletcher and his team offer is chronic care management (CCM) focused drug metabolite testing.
Such testing is critical because multimorbidity patients nearly always have polypharmacy needs that span multiple prescriptions. Unfortunately, this increases risks associated with drug-interactions and adverse drug events (ADEs), with patients frequently failing to fully inform physicians of the drugs they are taking. In addition, nonadherence to treatments may impact treatment efficacy, as well as pharmacogenomic variations that result in individual patients metabolizing drugs in different ways. The end result is increased health care expenses and poorer patient outcomes.
Fortunately, advanced workflows, elevated training protocol, and electronic records have combined to improve medication reconciliation in recent years. However, self-reporting on the part of patients is still fallible, and having incomplete information means increased ADE risk.
LifeBrite Laboratories’ lab analysis employs a proprietary chronic care management panel that is non-invasive and urine-based, and efficiently identifies the absence of drug metabolites that patients have been prescribed. With the test identifying metabolites associated with 125 common medications, CCM reports provide a clear indication of drugs being taken, or not taken, and allows for professional intervention if necessary.
Such testing is critical because multimorbidity patients nearly always have polypharmacy needs that span multiple prescriptions. Unfortunately, this increases risks associated with drug-interactions and adverse drug events (ADEs), with patients frequently failing to fully inform physicians of the drugs they are taking. In addition, nonadherence to treatments may impact treatment efficacy, as well as pharmacogenomic variations that result in individual patients metabolizing drugs in different ways. The end result is increased health care expenses and poorer patient outcomes.
Fortunately, advanced workflows, elevated training protocol, and electronic records have combined to improve medication reconciliation in recent years. However, self-reporting on the part of patients is still fallible, and having incomplete information means increased ADE risk.
LifeBrite Laboratories’ lab analysis employs a proprietary chronic care management panel that is non-invasive and urine-based, and efficiently identifies the absence of drug metabolites that patients have been prescribed. With the test identifying metabolites associated with 125 common medications, CCM reports provide a clear indication of drugs being taken, or not taken, and allows for professional intervention if necessary.
